Menopause brain fog is common, and supplement shelves are full of promises about it. A new randomized trial put one combination to the test, and the result is more interesting than a simple win. A blend of PQQ, GABA, caffeine and B vitamins beat placebo on several cognitive measures. One attention measure went the other way.
Here is what the study found, and what it can't tell you.
The quick version
The trial was published in BMC Nutrition (Kozma, Ratonyi, Takacs et al., 2026). It is open access: https://doi.org/10.1186/s40795-026-01535-6. It is registered at ClinicalTrials.gov as NCT06748989.
- Who: 63 healthy postmenopausal women completed the study, 30 on the supplement and 33 on placebo.
- What: A multi-component supplement with PQQ (pyrroloquinoline quinone), GABA, caffeine, vitamins and minerals, versus a matching placebo.
- How long: 6 weeks.
- How measured: The CNS Vital Signs computerized neurocognitive battery, taken at baseline and at the end.
- Design: Randomized 1:1, double-blind, placebo-controlled. Analysis was ANCOVA adjusted for baseline scores.
The headline numbers
The primary endpoint was the Neurocognition Index (NCI), a global score. Compared with placebo, the supplement group improved by an adjusted +5.89 points (95% CI 1.27 to 10.52; p = 0.013).
Several secondary domains also favored the supplement:
- Memory: +7.86 points (p = 0.020)
- Visual Memory: +7.97 points (p = 0.030)
- Cognitive Flexibility: +7.57 points (p = 0.039)
- Executive Functioning: a favorable trend that just missed significance (p = 0.053)
The researchers concluded that the supplement was associated with better global cognitive performance and selected memory- and executive-related domains.
The plot twist: complex attention
The abstract reports a significant result for Complex Attention that ran in a direction different from the overall pattern. In plain terms, that domain did not follow the improvement seen elsewhere. The abstract does not explain why, and it doesn't give a number I can responsibly quote.
This matters for two reasons. It shows the effect was not a uniform lift across all of cognition. It is also a reminder that when a trial tests many domains, some results will land in unexpected places. That could reflect real effects, such as a stimulant ingredient affecting different tasks differently. It could also be chance. This study can't settle which.
Why these ingredients?
The authors say each ingredient has been individually linked to mechanisms that may support cognitive health. That is a rationale, not proof. This trial tested the blend as one product, so it can't say which ingredient did the work, whether they act together, or whether caffeine alone explains some of the effect. Caffeine is a known stimulant, so that last question is a fair one.
How much to trust it
Treat this as a promising early signal, not a verdict.
- Small and short. 63 completers over 6 weeks says nothing about long-term effects or brain health down the line. The confidence interval for the main result is wide (1.27 to 10.52), so the true effect could be small or fairly large.
- Many outcomes. The study looked at multiple cognitive domains. The abstract doesn't mention adjustment for multiple comparisons, so p-values between 0.01 and 0.04 should be read cautiously.
- A combination product. You can't take these results and assume any single ingredient works alone.
- Healthy women only. These were healthy postmenopausal participants. The results don't speak to women with diagnosed cognitive impairment, depression, sleep disorders or other conditions.
- Computerized testing. The CNS Vital Signs battery gives standardized scores, but test scores don't always match how women feel in daily life.
- Authors' own caveat. They state that larger studies are needed to confirm the findings and assess long-term effects.
I also couldn't check funding or conflicts of interest from the abstract. Read the full open-access paper before drawing conclusions about the product's sponsor.
Practical takeaways
Dose and timing: The abstract does not give per-ingredient doses or dosing schedules, so I won't guess. The only firm detail is that the trial lasted 6 weeks. If you are considering a product, check the full text and the product label, and don't assume a retail supplement matches the trial formula.
Who might be interested: Healthy postmenopausal women curious about cognitive support and willing to treat it as an experiment. That means a defined trial period, a note of how you feel, and realistic expectations.
Who should be cautious or skip it (general safety sense, not findings from this paper):
- Anyone sensitive to caffeine, or who already struggles with anxiety, palpitations or poor sleep.
- Anyone taking prescription medications, especially for mood, sleep or anxiety. GABA and caffeine could plausibly matter here, so ask a clinician or pharmacist.
- Anyone whose attention is the main complaint, given the complex attention result.
- Anyone whose brain fog is severe, sudden or worsening. That needs a medical evaluation, not a supplement.
Bottom line
In this small, 6-week randomized trial, a PQQ, GABA, caffeine and B-vitamin combination beat placebo on the global Neurocognition Index and on memory, visual memory and cognitive flexibility in healthy postmenopausal women. The complex attention result went the other way, and executive functioning only trended. The trial is encouraging, but it needs larger, longer replication before anyone should treat it as a fix for menopause brain fog.
Source: Kozma B, Ratonyi D, Takacs P, et al. BMC Nutrition, 2026. DOI: 10.1186/s40795-026-01535-6. Trial registration: NCT06748989. This article is for information only and isn't medical advice.